Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Exercise likely to be best treatment for depression in coronary heart disease

Written by | 24 Jul 2021

A study by RCSI indicates that exercise is probably the most effective short-term treatment for depression in people with coronary heart disease, when compared to antidepressants and psychotherapy… read more.

Ivermectin – the unfolding story

Written by | 24 Jul 2021

IMI has been reporting on ivermectin since December 2020, keeping our readers and viewers up-to-date with research and practice developments. To mark World Ivermectin Day (24th July 2021),… read more.

FDA approves Vaxneuvance (pneumococcal 15-valent conjugate vaccine) for the prevention of invasive pneumococcal disease in adults 18 years and older caused by 15 serotypes – Merck Inc.

Written by | 23 Jul 2021

Merck Inc., announced the FDA has approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes… read more.

Protecting the intellectual abilities of people at risk for psychosis

Written by | 23 Jul 2021

Université de Genève One person in 2000 suffers from a microdeletion of chromosome 22 that can lead to the development of psychotic disorders, such as schizophrenia, in adolescence…. read more.

Incyte announces positive phase III REACH3 study data published in NEJM for ruxolitinib in chronic graft-versus-host disease

Written by | 22 Jul 2021

Incyte announced that positive data from the Phase III REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi)… read more.

Antibody-targeted immunotoxins could help treat liver fibrosis

Written by | 22 Jul 2021

University of California – San Diego In mouse models of human disease, immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and… read more.

FDA approves Kerendia in chronic kidney disease (CKD) associated with type 2 diabetes – Bayer HealthCare

Written by | 21 Jul 2021

Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.

Laughing gas relieves symptoms in people with treatment-resistant depression

Written by | 21 Jul 2021

Washington University School of Medicine A single, one-hour treatment that involves breathing in a mixture of oxygen and nitrous oxide — otherwise known as laughing gas — significantly… read more.

Hospitals prevent deadly fungal infection during pandemic

Written by | 20 Jul 2021

As COVID-19 infections threatened to overwhelm hospitals in March 2020, infection control specialists worried not just about SARS-CoV-2 but also about other viral, bacterial and fungal diseases. C…. read more.

Young male students at the centre of HIV surge

Written by | 20 Jul 2021

There has been a rapid rise in the number of human immunodeficiency virus (HIV) infections in China since the dawn of the 21st century. In the recent past,… read more.

EMA boost for COVID-19 vaccine production

Written by | 19 Jul 2021

The European Medicines Agency has approved additional manufacturing capacity for two companies producing vaccines against COVID-19. The news comes as European countries continue to roll out vaccines amid… read more.

Immunologists discover ‘spider web’ mechanism that traps viruses

Written by | 19 Jul 2021

Scientists at McMaster University in Toronto have discovered a previously unknown mechanism which acts like a spider web, trapping and killing pathogens such as influenza or SARS-CoV-2, the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.